Selene Therapeutics
Pioneering a new therapeutic strategy for treating refractory epilepsy – regulation of the neuronal activity set point by reduction of the neuronal mean firing rate (MFR).
Selene Therapeutics is at the forefront of developing new treatments for refractory epilepsy, a condition affecting over 50 million people globally. The company leverages cutting-edge science to target mitochondrial DHODH, a key player in maintaining metabolic homeostasis in hyperexcitable hippocampal circuits. By inhibiting DHODH, Selene Therapeutics aims to reduce spontaneous neuronal spiking activity, thereby stabilizing neuronal and network function. The company's technology, licensed from Ramot at Tel Aviv University, focuses on addressing the unmet needs of epileptic patients who do not respond to existing antiepileptic drugs. Selene Therapeutics operates in the biopharmaceutical market, primarily serving patients with refractory epilepsy. The business model revolves around research and development, with revenue generated through licensing agreements and potential future sales of their therapeutic solutions.
Keywords: refractory epilepsy, mitochondrial DHODH, metabolic homeostasis, neuronal activity, hippocampal circuits, antiepileptic drugs, biopharmaceutical, Ramot, Tel Aviv University, therapeutic strategy.